
30th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication: meeting report: 31 May to 2 June 2016 / World Health Organization. Regional Office for Europe
Tác giả : World Health Organization. Regional Office for Europe
Nhà xuất bản : World Health Organization. Regional Office for Europe
Năm xuất bản : 2016
Chủ đề : 1. Europe. 2. Poliomyelitis. 3. Poliovirus. 4. Public Health. 5. Technical documents.
Thông tin chi tiết
Tóm tắt : | 36 p. The 30th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication (RCC) reviewed annual updates submitted by the Member States of the Region on the status of the national polio eradication programme. The RCC concluded, based on available evidence, that there was no wild poliovirus (WPV) transmission in the WHO European Region in 2015, but that vaccine-derived poliovirus (VDPV) type 1 was in circulation in Ukraine. While all countries remain at risk of importation, Bosnia and Herzegovina, Romania and Ukraine remain at high risk of a sustained polio outbreak following importation due to low population immunity. The RCC expressed concern at the number of countries, particularly those in the Balkans, where vaccine coverage is in decline, and the quality of poliovirus surveillance has reduced. The Commission was encouraged that the planned switch to bivalent oral polio vaccine (bOPV) throughout the Region in April 2016 was completed successfully, but concerns exist that this Region has been adversely affected by delays in global availability of inactivated polio vaccine (IPV). Affected countries in the Region included those remaining at risk of importation due to their close proximity to the last two endemic countries in the world. The RCC commended the extent and quality of work conducted in meeting the requirements for laboratory containment of poliovirus and noted that the Region is in advance of other WHO regions in implementing the Global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of OPV use (GAPIII). Because of the number of global-level polio and enterovirus laboratories and Europe-based polio vaccine manufacturers likely to require polio essential facility (PEF) status, the Region will face a considerable workload in fully implementing all polio containment requirements. |
Thông tin dữ liệu nguồn
Thư viện | Ký hiệu xếp giá | Dữ liệu nguồn |
---|---|---|
![]() |
|
https://iris.who.int/handle/10665/371333 |